Uppsala: Animal testing alternatives took centre stage among medicine regulators on 1 October 2026, when the European Medicines Agency endorsed a joint statement from the International Coalition of Medicines Regulatory Authorities that calls for non-animal methods across the whole lifecycle of a medicine. EMA, the UK’s MHRA, Ireland’s HPRA and Switzerland’s Swissmedic led the drafting, and the coalition’s plenary adopted the text.
The long-term goal is to replace animal testing at every stage, from early candidate screening and development through preclinical testing, licensing and post-authorisation. The statement stresses that this requires a cautious, stepwise move to methods that are scientifically valid and acceptable to regulators, not a sudden switch.
For new medicines, the coalition asks developers worldwide to use animal testing alternatives that regulators can accept without compromising scientific quality. Regulators, in turn, should support and facilitate those efforts. That division of labour matters, because developers rarely adopt a new test until they are confident an authority will take the data.
Batch release testing gets specific attention. Regulators should encourage non-animal batch release tests and challenge proposed animal use. They should approve in vivo batch release testing only when it is scientifically justified and no equivalent or superior non-animal method exists, and they should review and amend existing in vivo requirements.
Developers have a practical stake. Companies that invest in cell-based models, computer simulation or other animal testing alternatives want assurance that authorities in several regions will accept the data, because duplicate studies for each market erode the savings. The statement tries to supply that assurance by pushing regulators toward common expectations.
The statement admits that regions will move at different speeds, yet it urges manufacturers, developers and regulators to work together toward harmonised implementation. EMA says international harmonisation through the coalition is central to its long-standing commitment to replace, reduce and refine animal use, known as the 3Rs.
Progress on animal testing alternatives is already visible. From 2015 to 2023, annual animal use for regulatory purposes in pharmaceuticals roughly halved. In June, the European Commission also presented a roadmap for phasing out animal testing in chemical safety assessments, so the medicines statement lands inside a wider EU push.
No deadlines follow from the text. The coalition is simply calling on medicine developers, manufacturers, regulators and national control laboratories to continue to advance non-animal approaches. The real measure of animal testing alternatives will be how many regulators change batch release rules and accept new methods in routine submissions over the next few years.
